

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 0690)

VOLUNTARY ANNOUNCEMENT IN RELATION TO THE SIGNING OF THE LETTER OF INTENTION FOR AN EXCLUSIVE COOPERATION FRAMEWORK AGREEMENT

This voluntary announcement is made by Uni-Bio Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide shareholders and potential investors of the Company with information about the latest business development of the Group.

LETTER OF INTENTION

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that after the trading hours of The Stock Exchange of Hong Kong Limited on 13 June 2019, Uni-Bio Science Healthcare (Beijing) Co. Limited (“**Uni-Bio Science Healthcare**”), a wholly-owned subsidiary of the Company, entered into a non-legally binding letter of intention for an exclusive cooperation framework agreement (the “**Letter**”) with Kai Ping Shi Jian Bao Zhen Tourism Development Company Limited* (開平時間寶鎮旅遊發展有限公司) (the “**Cooperation Partner**”). The Cooperation Partner is a company established for the Kai Ping Forest Ecological Wellness Tourism Project (the “**Project**”). The Project license has been approved by the Guangdong Provincial Development and Reform Commission on 23 April 2019. The Project covers an area of approximately 2.916 million square meters, with a gross floor area of approximately 0.7012 million square meters. Major elements of the Project construction include a three-star resort hotel, a five-star hot spring hotel/log cabin zone, specialized healthcare facilities (including a clinic, a hospital, a health club and a health resort), a forest ecological wellness zone formed by 3000 two-storied healthcare residences, an aerospace club, a theme park, a theme garden, and resort roads and other relevant ancillary facilities of the resort. It is targeted to attract 2 million annual visits. Based on ecological resources, the Project is a nature wellness tourism project that integrates regimen, elderly-care, the healthcare industry, and leisure tourism facilities.

Pursuant to the Letter, both parties preliminarily agree to enter into a comprehensive and exclusive cooperation framework agreement, and to discuss the possibility of building a joint venture, based on the following issues:

- To provide healthcare related services for patients diagnosed with chronic diseases within the Project area, especially in the fields of diabetes and osteoporosis; and
- To set up and operate hospitals/clinics within the Project area, in order to support phase I and phase IV clinical trials of the Group's future research on chronic diseases, especially in the fields of diabetes and osteoporosis.

The Board is of the view that the entering into the Letter is beneficial to the Company as the Project would enable the parties to leverage on their respective strengths, resources and expertise to build a stable and mutually-beneficial strategic partnership.

Pursuant to the Letter, a six-month exclusivity period has been granted during which the parties will negotiate exclusively with each other, and the Group will also further conduct due diligence and financial viability research in relation to the Project. The parties should negotiate in good faith to enter into a formal agreement upon or before the expiry of the exclusivity period (or such later date as may be agreed between the Company and the Cooperation Partner) as soon as possible.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, each of the Cooperation Partner and its ultimate beneficial owners is a third party independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

This announcement is prepared in both Chinese and English. In the event of discrepancy, the Chinese version shall prevail.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 13 June 2019

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* *For identification purposes only*